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Abstract
Background: Inflammation may be involved in the pathogenesis of Alzheimer’s disease (AD). There has been little
success with anti-inflammatory drugs in AD, while the promise of anti-inflammatory treatment is more evident in
experimental models. A new anti-inflammatory strategy requires a better understanding of molecular mechanisms.
Among the plethora of signaling pathways activated by b-amyloid (Ab) peptides, the nuclear factor-kappa B
(NF-B) pathway could be an interesting target. In virus-infected cells, double-stranded RNA-dependent protein
kinase (PKR) controls the NF-B signaling pathway. It is well-known that PKR is activated in AD. This led us to study
the effect of a specific inhibitor of PKR on the Ab42-induced inflammatory response in primary mixed murine
co-cultures, allowing interactions between neurons, astrocytes and microglia.
Methods: Primary mixed murine co-cultures were prepared in three steps: a primary culture of astrocytes and
microglia for 14 days, then a primary culture of neurons and astrocytes which were cultured with microglia purified
from the first culture. Before exposure to Ab neurotoxicity (72 h), co-cultures were treated with compound C16, a
specific inhibitor of PKR. Levels of tumor necrosis factor-a (TNFa), interleukin (IL)-1b, and IL-6 were assessed by
ELISA. Levels of PT451-PKR and activation of IB, NF-B and caspase-3 were assessed by western blotting. Apoptosis
was also followed using annexin V-FITC immunostaining kit. Subcellular distribution of PT451-PKR was assessed by
confocal immunofluorescence and morphological structure of cells by scanning electron microscopy. Data were
analysed using one-way ANOVA followed by a Newman-Keuls’ post hoc test
Results: In these co-cultures, PKR inhibition prevented Ab42-induced activation of IB and NF-B, strongly
decreased production and release of tumor necrosis factor (TNFa) and interleukin (IL)-1b, and limited apoptosis.
Conclusion: In spite of the complexity of the innate immune response, PKR inhibition could be an interesting
anti-inflammatory strategy in AD.
Background
One hundred years ago, Fisher [1] proposed that the
deposition of a foreign substance in the human cortex of
patients with Alzheimer’s disease (AD), later identified as
fibrillated amyloid-b peptide (Ab), could induce a local
inflammatory reaction associated with regenerative
changes in the surrounding neurons. The innate immune
response in AD is marked by the production of various
complement components (C1q, C3, C5) and formation of
the terminal membrane attack complex, resulting in
attraction and activation of microglia and astrocytes
[2-6]. Both microglia and astrocytes produce multiple
pro-inflammatory factors, including cytokines (tumor
necrosis factor-a (TNFa), interleukin (IL)-1, and IL-6),
chemokines (CC- and CXC-chemokine ligands such as
CCL2, 3, and 5; and CXCL10), reactive oxygen species,
and cyclooxygenase 2 (COX2); and express various com-
plement receptors [7,8]. This inflammatory response
* Correspondence: guylene.page@univ-poitiers.fr
1Research Group on Brain Aging, GReViC EA 3808, 6 rue de la Milétrie BP
199, 86034 Poitiers Cedex, France
Full list of author information is available at the end of the article
Couturier et al. Journal of Neuroinflammation 2011, 8:72
http://www.jneuroinflammation.com/content/8/1/72
JOURNAL OF 
NEUROINFLAMMATION
© 2011 Couturier et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
aims to enhance the clearance of Ab by the phagocytic
role of both microglia and astrocytes. Although activation
of the complement system or a lipopolysaccharide (LPS)
treatment in amyloid precursor protein (APP) transgenic
mice increases phagocytosis of Ab and might limit
pathology by activating immune responses [8,9], the ben-
eficial role of inflammation in AD does not seem to be
sufficient to halt or reverse the disease. It fails to slow
progression of the major histopathological hallmarks
(amyloid plaques and neurofibrillar tangles) and cognitive
impairment. The innate immunity system might be neu-
roprotective as far as phagocytosis is elicited, but later in
the disease proinflammatory responses could turn the
innate immunity into the driving force in AD
pathogenesis.
Increasing evidence suggests that inflammation signifi-
cantly contributes to the pathogenesis of AD. It is
known that Ab oligomers and fibrils, as danger-asso-
ciated molecular patterns (DAMPs), can interact with
different pattern recognition receptors (PRRs) such as
scavenger receptors, toll-like receptors (TLRs), and the
receptor for advanced glycation end products (RAGE) in
both glial cells and neurons [10,11]. PRRs can trigger
phagocytic uptake of Ab but also can induce proinflam-
matory signaling pathways such as IB kinase (IKK), Jun
kinase (JNK) p38 and glycogen synthase kinase 3b
(GSK-3b) [10].
Many cytokines such as TNFa and IL-1b, and chemo-
kine signaling (CXCR2 signaling) can promote Ab pro-
duction by modulating g-secretase activity in neurons
[12,13]. Some studies have also demonstrated that IL-1b
induces phosphorylation of tau protein and triggers for-
mation of paired-helical filaments (PHFs) which aggre-
gate into neurofibrillary tangles [14,15]. Inflammation in
AD could also trigger functional impairment since
inflammatory molecules such as TNFa, IL-1 and IL-6
are able to suppress hippocampal long term potentiation
[16,17]. Furthermore, many studies have shown a signifi-
cant increase of various inflammatory mediators in
plasma and in peripheral blood mononuclear cells
(PBMCs) of patients with AD compared to age-matched
controls [18,19].
In addition, many prospective epidemiological studies
have indicated that non-steroidal anti-inflammatory
drugs (NSAIDS) might delay the onset and the progres-
sion of AD [20]. However, clinical trials with COX-2
inhibitors have yielded negative results, and the rele-
vance of specific COX inhibitors and other NSAIDS has
become more and more questionable [21]. There are
many reasons to explain the failure of these trials: tim-
ing of treatment, dosing, and the specificities of admini-
strated NSAIDS are the most frequently cited. A recent
small, open-label pilot study suggested that inhibition of
the inflammatory cytokine TNF-a with perispinal
administration of etanercept, a potent anti-TNF fusion
protein, might lead to sustained cognitive improvement
in patients with mild, moderate, or severe AD [22].
These results need to be confirmed.
The cellular and molecular components of the innate
inflammatory response associated with slowly progres-
sive degenerative disease are not clearly identified. In
this response, Ab could involve different PRRs, activat-
ing protein kinases such as IKKs which trigger proin-
flammatory responses via nuclear factor-kappa B (NF-
B), known as the major transcriptional factor of a wide
range of cytokines, that could in turn maintain NF-B
activation and establish a positive autoregulatory loop
that could amplify the inflammatory response and
increase the duration of chronic inflammation [23]. The
modulation of NF-B activation in AD may be a neuro-
protective strategy. A recent study revealed that an inhi-
bitor of NF-B ameliorates astrogliosis but has no effect
on amyloid burden in APPswePS1dE9 [24], probably
due to late timing of the treatment after the beginning
of amyloid deposits. The IKK/NF-B signaling pathway
is under the control of other kinases, in particular the
double-stranded RNA-dependent protein kinase (PKR),
well described in AD and associated with degenerating
neurons and cognitive decline [12,25-30]. Indeed, in stu-
dies using different virus-infected cells, it has been
shown that PKR can phosphorylate IKK, which phos-
phorylates IB, leading to disruption of the cytosolic IB-
NF-B complex. This allows NF-B to translocate from
the cytoplasm to the nucleus, where it binds to its speci-
fic sequences of DNA called response elements of the
target genes, including those involved in the immune
response (IL-2), inflammatory response (TNFa, IL-1, IL-
6), cell adhesion (I-CAM, V-CAM, E-selectin) cell growth
(p53, Ras, and c-Myc) and apoptosis (TNF receptor-asso-
ciated factor 1 and 2) [31-33]. Furthermore, it has been
shown that TNF-induced NF-B activation, IKK activa-
tion, IBa phosphorylation, IBa degradation and NF-
B reporter gene transcription are all suppressed in PKR
gene-deleted fibroblasts, underlining the fact that NF-B
is a downstream target of PKR [34].
The aim of the present study was to determine
whether PKR can control activation of the NF-B path-
way and cytokine production (TNF, IL-1b, and IL-6) in
primary mouse co-cultures that contain the three main
cellular actors in brain: neurons, astrocytes and micro-
glia. While neurons are traditionally passive bystanders
in neuroinflammation, they are able to produce inflam-
matory mediators such as IL-1b, IL-6, TNFa [15,35,36].
Although this integrated in vitro model does not corre-
spond exactly to the brain environment, it includes the
major cell types of brain and maintains the interactions
between these three cellular actors which could modu-
late the inflammatory response of each one.
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For this purpose, before exposure to Ab neurotoxicity,
co-cultures were treated with compound C16, a specific
inhibitor of PKR [37]. Analysis of results shows that
inhibition of PKR prevents activation of NF-B, asso-
ciated with a strong decrease in production and release
of TNFa and IL-1b, and limited apoptosis. Keeping in
mind the complexity of the innate immune response,
inhibition of PKR could be an interesting strategy to res-
cue the inflammatory process in AD.
Methods
Chemical products
Sodium fluoride (NaF), phenylmethylsulfonyl fluoride
(PMSF), protease and phosphatase inhibitor cocktails,
dithiothreitol (DTT), 0.01% poly-L-lysine solution, Per-
coll®, sterile filtered dimethylsulfoxide Hybri-Max®
(DMSO), Triton X-100, paraformaldehyde (PFA), annex-
inV-fluorescein isothiocyanate (FITC) apoptosis detec-
tion kit and all reagent-grade chemicals for buffers were
purchased from Sigma (St Quentin Fallavier, France);
DMEM (1 g/L), MEM and Neurobasal media, B-27 Sup-
plement, 200 mM L-glutamine, 5,000 units of penicillin
(base) and 5,000 μg of streptomycin (base)/mL (PS) mix-
ture, 0.5 g/L Trypsin/0.2 g/L EDTA 4Na, Fetal Bovine
Serum, Certified (FBS), Horse Serum, NuPAGE®
Novex® Bis-Tris Mini Gels, NuPAGE® LDS 4X LDS
Sample Buffer, NuPAGE® Sample Reducing Agent
(10X), NuPAGE® MES SDS Running Buffer and
NuPAGE® Antioxidant, iBlot® Gel Transfer Device
(EU), the Prolong Gold antifade reagent with 4’,6-diami-
dino-2-phenylindole (DAPI) and the Zenon mouse IgG
labelling kit from Gibco-Invitrogen (Fisher Bioblock
Scientific distributor, Illkirch, France); the imidazolo-
oxindole compound C16 from Merck Chemicals Calbio-
chem® (Nottingham, UK). For western blot, primary
antibodies and secondary anti-rabbit IgG antibody con-
jugated with horseradish peroxydase were purchased
from Cell Signalling (Ozyme, St Quentin Yvelines,
France) excepted anti-PT451-PKR from Eurogentec (Sera-
ing, Belgium), anti-b tubulin and anti-b actin from
Sigma (St Quentin Fallavier, France), anti-amyloid pep-
tide (clone WO2, recognizes amino acids residues 4-10
of Ab) from Millipore (St Quentin-Yvelines, France),
peroxidase-conjugated anti-mouse IgG from Amersham
Biosciences (Orsay, France). For immunofluorescence,
anti-glial fibrillary acidic protein (GFAP) antibodies
were purchased from Cell Signalling (Ozyme, St Quen-
tin Yvelines, France), microtubule associated protein 2
(MAP2) from Abcam (Paris, France), macrosialin or
murine homologue of the human CD68 from AbD Sero-
tec (Düsseldorf, Germany), anti-PT451-PKR from Bio-
source (Nivelles, Belgium), secondary antibodies from
DakoCytomation, (Trappes, France) and IgG- and pro-
tease-free bovine serum albumin (BSA) from Jackson
ImmunoResearch Europe Ltd (Interchim distributor,
Montluçon, France).
Primary murine mixed neuron-astrocyte-microglia
cultures
First, primary glial cultures were prepared from C57BL/
6J mouse embryos of 18 days. Brains were quickly
removed, and cerebral cortico-hippocampal regions
were dissected in ice-cold and sterile 1X PBS (154 mM
NaCl, 1.54 mM KH2PO4, 2.7 mM Na2HPO4 7H2O, pH
7.20 ± 0.05) containing 18 mM glucose and 1% PS as
previously described [38]. Cells were then dissociated
mechanically using a pipette into DMEM/1% PS, trans-
ferred into tubes containing FBS at the bottom (1 mL/
30 mL cell suspension) and centrifuged at 300 × g for
10 min at 4°C. The cell pellet was suspended into
DMEM/1% PS and centrifuged again. This step was
repeated once. After the centrifugation, cells were sus-
pended into DMEM/10% FBS/1% PS, seeded at a density
of 4 × 105 cells/mL in Nunc EasYFlask™ (75 cm2)
coated with 0.001% poly-L-lysine and then incubated at
37°C in a humidified 5% CO2 atmosphere. Medium was
replaced every five days. These cells were cultured until
day 14, the day of microglia purification.
Second, primary cultures with neurons and astrocytes
were prepared from cortex and hippocampus of C57BL/
6J mouse embryos of 18 days as above. Cells were sus-
pended in MEM/Neurobasal (1:1) supplied with 18 mM
glucose, B-27 Supplement, 1% glutamine, 2.5% FBS,
2.5% horse serum and 1% PS, and seeded in 6-well
plates (106 cells per well) coated with 0.001% poly-L-
lysine. Cultures were then maintained at 37°C in a
humidified 5% CO2 atmosphere. At day 5, neurons and
astrocytes were cultured with microglia purified from
the primary culture described above.
Third, microglia were purified from glial cultures on
day 14 as previously described with some modifications
[39]. Briefly, confluent glial cultures were dissociated
with trypsin/EDTA and cell suspensions were suspended
in 1 mL of 70% isotonic Percoll and transferred into a 5
ml glass tube. Two mL of 50% isotonic Percoll were
gently layered on top of the 70% layer and then 1 mL of
1X PBS layered on top of 50% isotonic Percoll layer.
Tubes were centrifuged at 1200 × g for 45 min at room
temperature (RT) with a program including minimum
acceleration and brake in a swinging bucket rotor.
Purified microglia occupied the interface between 70
and 50% isotonic Percoll. The top interface between 1X
PBS and 50% isotonic Percoll containing all other cen-
tral nervous system (CNS) elements was carefully
removed and microglia layer was transferred into a new
tube and washed twice by adding 1 mL PBS and centri-
fuged at 500 × g for 5 min at RT. Cells were counted
and seeded at the density of 150,000 cells per well into
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6-well plates containing the primary culture of neurons/
astrocytes to 5 days old in order to obtain a density of
microglia close to that already described. Indeed, the
density of microglia in the CNS of the normal adult
mouse brain is variable depending on the brain region
and represents 5% in the cerebral cortex, according to
Lawson et al. [40]. The mixed murine co-cultures with
neurons, astrocytes and microglia were then used three
days later for experiments and a fourfold confocal stain-
ing with cell and nucleus markers (DAPI, MAP-2, GFAP,
CD68 for nuclei, neurons, astrocytes and microglia,
respectively) was investigated in cells seeded on poly-L-
lysine-coated glass coverslips to quantify neurons, astro-
cytes and microglia. In additional file 1, figure S1, we
show that neurons, astrocytes and microglia represent
about 36, 57 and 6% of total cells, respectively, i.e. close
to what is physiologically observed in the cortex.
Chemical treatments
Co-cultures were treated with either C16 (specific inhibi-
tor of PKR) at different concentrations (210 nM (IC50)
and 1 μM) or DMSO (vehicle of C16) at less than 1%, in
serum-free MEM:Neurobasal (1:1)/1% glutamine/1% PS
medium 1 hour before 20 μM Ab42 (or exactly 11 nmol
in 550 μL of medium in each well receiving Ab42) for 72
h at 37°C. Ab42 was previously incubated 48 h at 37°C
for aggregation as recommended by the Merck Chemical
supplier [41]. The concentration of Ab42 was chosen
based on previous work in primary cultures [38,42]. After
treatment, media were conserved in order to analyse
Ab42 monomers and oligomers by immunoblotting and
fibrillar form of Ab42 by scanning electron microscopy
in our experimental conditions (see the additional file 2,
Figure S2). Results show the presence of a mix composed
with monomers, oligomers (8 and 12 kDa) and a dense
network of fibrils. As the specific toxicity of these differ-
ent states of Ab is not clearly demonstrated, we decided
to incubate cells with this whole mixture.
Cell lysis and nuclear extracts
After treatment, media were stored at -80°C until used
for ELISA of cytokines. Cells were then washed with
PBS and lysed in ice-cold lysis buffer (50 mM Tris-HCl,
50 mM NaCl pH 6.8, 1% (v/v) Triton X-100, 1 mM
PMSF, 50 mM NaF, 1% (v/v) protease inhibitor and 1%
(v/v) phosphatase inhibitor cocktails). Lysates were soni-
cated for 10 sec and centrifuged at 15,000 × g for 15
min at 4°C. The supernatants were collected and ana-
lyzed for protein determination using a protein assay kit
(Biorad, Marnes-la-Coquette, France). Samples were fro-
zen at -80°C until further analysis.
Nuclear extracts were prepared as previously described
[43]. Firstly, the cytoplasmic fraction was isolated and
discarded, and the nuclear pellet was then lysed in
nuclear lysis buffer (20 mM Hepes pH 7.9, 400 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.5 mM
PMSF, 1% of protease and 1% phosphatase inhibitor
cocktails) during 2 h at 4°C. Then, vials were centri-
fuged at 1,600 × g for 5 min at 4°C and the supernatant
was isolated. The quantity of total protein was measured
with a Biorad protein assay kit.
Enzyme-linked immunosorbent assay (ELISA)
Commercially available ELISA kits were used for asses-
sing TNFa (sensitivity: 2 pg/mL), IL-1b (sensitivity: 15
pg/mL) and IL-6 (sensitivity: 2 pg/mL) according to the
manufacturers’ instructions (BioLegend, Ozyme, St
Quentin Yvelines, France). The range of analysis was
between 7.8-6000 pg/mL. Cell lysates were diluted (1:2)
with the assay diluents and all steps were performed at
RT. The enzymatic reaction was stopped after 15 min
incubation with tetramethylbenzidine (TMB) substrate
by adding 2N H2SO4 and the optical density (OD) was
read at 450 nm within 30 min, using the Multiskan®
spectrum spectrophotometer. The cytokine levels were
then calculated by plotting the OD of each sample
against the standard curve. The intra- and inter-assay
reproducibility was > 90%. OD values obtained for
duplicates that differed from the mean by greater than
10% were not considered for further analysis. For conve-
nience all results are expressed in pg/mL and in pg/mg
protein for culture medium and cell lysates, respectively.
Immunoblotting
Samples (30 μg proteins of cell lysates or nuclear
extracts) were prepared for electrophoresis by adding
NuPAGE® LDS 4X LDS sample buffer and NuPAGE®
Sample Reducing Agent (10X). Samples were then
heated up 100°C for 5 min and loaded into NuPAGE®
Novex® Bis-Tris Mini Gels, and run at 200 V for 35
min in NuPAGE® MES SDS running buffer containing
0.5% NuPAGE® antioxidant. Gels were transferred to
nitrocellulose membranes using the iBlot® Dry blotting
system set to program 20V for 7 min. Membranes were
washed for 10 min in Tris-buffered saline/Tween
(TBST: 20 mM Tris-HCl, 150 mM NaCl, pH 7.5, 0.05%
Tween 20) and blocked 2 h in TBST containing 5% non
fat milk or 5% bovine serum albumin (BSA).
Blots were incubated with primary antibody in block-
ing buffer overnight at 4°C. Antibodies used were rabbit
anti-PT451-PKR (1:100), mouse anti-PS32/36-IB (1:500),
rabbit anti-IB (1:500), rabbit anti-PS536-NF-Bp65
(1:500), rabbit anti-NF-Bp65 (1:500) and rabbit anti-
caspase3 8G10 (1:500) which detects endogenous levels
of full-length and large fragments of caspase-3 resulting
from cleavage at aspartic acid 175. Membranes were
washed 2 times with TBST and then incubated with the
peroxidase-conjugated secondary antibody either anti-
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rabbit or anti-mouse IgG (1:1000) according to the ori-
gin of primary antibody during 1 hour at RT. Mem-
branes were washed again and exposed to the
chemiluminescence ECL luminol plus western blotting
system (Amersham Biosciences, Orsay, France) followed
by signal capture with the Gbox system (GeneSnap soft-
ware, Syngene, Ozyme distributor). After 2 washes in
TBST, membranes were probed with mouse antibody
against tubulin (1:10000) or actin (1:100000) overnight
at 4°C. They were then washed with TBST, incubated
with peroxidase-conjugated secondary antibody anti-
mouse (1:1000) for 1 h, exposed to the chemilumines-
cence ECL luminol western blotting system and signals
were captured. Automatic image analysis software was
supplied with Gene Tools (Syngene, Ozyme distributor).
Ratios protein/tubulin or actin were calculated and are
shown in the corresponding figures.
Immunofluorescence
After treatment, cells on coverslips were washed once
with PBS and fixed with 4% PFA for 15 min at RT.
After three washes with PBS, the permeabilizing and
blocking PBS buffer (137 mM NaCl, 2.7 mM KCl, 1.7
mM KH2PO4, 10.14 mM Na2HPO4, pH 7.4 containing
0.3% triton X-100 and 5% of IgG- and protease-free
BSA) was added during 1 h at RT.
Staining of neurons, astrocytes and microglia was per-
formed by incubating coverslips overnight at 4°C with a
mix containing rabbit anti-MAP2 (1:50), mouse anti-
GFAP (1:100) and rat anti-CD68 (1:25) in PBS contain-
ing 0.3% triton X-100 and 1% of BSA. Cells were then
rinsed twice with PBS before 1 h incubation at RT with
the mix containing secondary antibodies: swine anti-rab-
bit FITC (1:20), goat anti-mouse AlexaFluor 647 (1:25)
and goat anti-rat R-Phycoerythrin (RPE) (1:25) diluted
in PBS/0.3% triton X-100/1%BSA. Finally, cells were
washed twice in PBS and twice in distilled water before
using the Prolong Gold antifade reagent with DAPI.
Staining of PT451-PKR and cell marker (MAP2, GFAP
or CD68) was performed in PBS/0.3% triton X-100/1%
BSA overnight at 4°C by using rabbit anti-PT451-PKR
(1:25) with chicken anti-MAP2 (1:100) and mouse anti-
GFAP (1:100). After incubation, cells were washed twice
with PBS before incubated with swine anti-rabbit (1:30)
conjugated with tetramethylrhodamine isomer R
(TRITC), goat anti-chicken FITC (1:50) and goat anti-
mouse AlexaFluor 647 (1:25) for 1 h at RT. A sequential
labelling for PT451-PKR and CD68 was performed.
Firstly, cells were incubated with anti-CD68 antibodies
overnight at 4°C, washed and incubated with goat anti-
rat RPE. Secondly, cells were incubated with anti-PT451-
PKR overnight at 4°C, washed and incubated with swine
anti-rabbit FITC (1:20). Finally, coverslips were washed
and mounted as described above.
Annexin V-FITC labels phosphatidylserine sites on the
membrane surface. The kit used also includes propidium
iodide (PI) to label cellular DNA in necrotic cells where
the cell membrane has been totally compromised. For
this labelling, cells were incubated with annexinV-FITC
(1:50) and PI (1:100) in 1X binding buffer for 10 min at
RT. Cells were then fixed with 4% PFA for 15 min at
RT. After three washes with PBS, cells were incubated
in the permeabilizing and blocking PBS buffer for 1 h at
RT and with anti-MAP2 and anti-GFAP or with anti-
CD68 in the same experimental conditions as described
for the previous staining of PT451-PKR.
Multiply labelled samples were examined with a spec-
tral confocal FV-1000 station installed on an inverted
microscope IX-81 (Olympus, Tokyo, Japan) with Olym-
pus UplanSapo x60 water, 1.2 NA, objective lens. Fluor-
escence signal collection, image construction, and
scaling were performed using the control software
(Fluoview FV-AS10, Olympus). Multiple fluorescence
signals were acquired sequentially to avoid cross-talk
between image channels. Fluorophores were excited
with 405 nm line of a diode (for DAPI), 488 nm line of
an argon laser (for Alexa 488 or FITC), 543 nm line of
an HeNe laser (for TRITC and RPE) and the 633 nm
line of an HeNe laser (for AlexaFluor 647). Emitted
fluorescence was detected through spectral detection
channels between 425-475 nm and 500-530 nm, for blue
and green fluorescence, respectively and through a 560
nm and a 650 nm long pass filters for red and far red
fluorescence, respectively. The images then were merged
as an RGB image.
Scanning electron microscopy
Cells were seeded on poly-L-lysine-coated glass cover-
slips at the same density described above. Treated pri-
mary co-cultures were rinsed briefly with PBS and fixed
for 2 h at 4°C with 100 μM phosphate buffer (pH 7,4)
containing 3% glutaraldehyde. After several rinses, they
were post-fixed 1 h in 1% osmium tetroxide. Cells were
washed again and dehydrated in acetone. Thereafter,
samples were critical point-dried with a BAL-TEC CPD
030 using acetone and liquid carbon dioxide as the tran-
sition fluid. The dried specimens were coated with gold
(25-35 nm thickness) using a sputtering device (BAL-
TEC LCD 005). The samples were examined and photo-
graphed with a JEOL JSM-840 electron microscope.
Statistics
Results are expressed as means ± SEM. Data for multi-
ple variable comparisons were analysed by a one-way
ANOVA followed by a Newman-Keuls’ test as a post
hoc test according to the statistical program GraphPad
Instat (GraphPad Software, San Diego, CA, USA). The
level of significance was p < 0.05.
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Results
Toxicity of compound C16 in primary murine mixed co-
cultures
Compound C16 is one of the most specific valuable imi-
dazolo-oxindole inhibitors of PKR autophosphorylation
that also rescues a PKR-induced translational block in a
rabbit reticulocyte lysate system at micromolar concen-
trations [37]. Furthermore, previous data have shown
that 1 μM C16 markedly reduces levels of PT451-PKR
and caspase-3 activity in Ab42-treated SH-SY5Y cells
[27,43]. The T451 phosphorylated site in the PKR acti-
vation loop is required in vitro and in vivo for high-level
kinase activity [44].
We first evaluated toxicity of compound C16 at 210
nM (IC50) and 1 μM compared to its DMSO vehicle ( <
1%). By using scanning electron microscopy, we showed
that the majority of cultured cells were neurons and
astrocytic glial cells (Figure 1). Amongst these were
some round cellular elements ranging from 10 to 15 μm
in diameter which were identified as microglia cells. In
experimental conditions with DMSO or 210 nM C16,
microglia looked like spherical smooth cells in contact
with neurons and the astroglial layer. No reactive micro-
glia were observed in these control conditions. However,
1 μM C16 greatly affected the integrity of cells in co-
cultures, with neuronal death, disruption of axonal net-
work and activated astrocytes. The microglia looked like
macrophages (Figure 1). Based on these observations,
further experiments were performed with the effective
concentration 210 nM, corresponding to IC50 of com-
pound C16 [37].
Prevention of Ab-induced PKR activation and NF-B/IB
signaling pathway by compound C16
At its IC50, C16 significantly reduced by 33% the pro-
minent activation of PKR induced by 20 μM Ab42 over
72 h in the co-cultures as shown by immunoblotting
from nuclear extracts (Figure 2). Confocal staining of
PT451-PKR confirmed the activation of PKR under Ab42
exposure compared to DMSO-treated cells (Figure 3C,
G and 3K, Oversus 3A, E and 3I, M, respectively). More-
over, co-staining with the neuronal marker MAP2 indi-
cated that PT451-PKR was present in neurons, with
intense perinuclear, nuclear and axonal staining, com-
pared to DMSO-treated cells (Figure 3: C, G compared
to A, E). Treatment with C16 decreased perinuclear and
nuclear staining induced by Ab42, but some axons
remained stained (Figure 3D, H). The co-cultures incu-
bated with compound C16 alone resembled those incu-
bated with DMSO alone (Figure 3B, F, J, Nversus 3A, E,
I, M, respectively). In astrocytes labeled by antibodies
against GFAP, a diffuse cytoplasmic staining of PT451-
PKR and a robust staining in spine-like structures of
astrocytic processes with Ab42 (Figure 3C and 3G) were
observed and were well prevented by C16 treatment
(Figure 3D, H). Microglia stained with anti-CD68 anti-
bodies displayed a high level of activated PKR after 72 h
of Ab42 exposure (Figure 3K, O) compared to DMSO-
treated cells (Figure 3I, M). There was also a change in
cellular morphology; microglia were activated with
appearance of thick processes and irregular shape with
Ab42 treatment (Figure 3K, O). C16 partially rescued
this activation of PKR in microglia. Furthermore, we
found only microglia with no thick processes around
cell bodies as with C16 alone (Figure 3. merge images J
and L).
The same experimental conditions were followed to
study activation of the NF-B/IB signaling pathway.
Results obtained by immunoblotting from cell lysates
are presented as the ratio of phospho-protein/total pro-
tein in order to evaluate the activation of both proteins.
The results show a significant increase in phosphoryla-
tion of IB at serine 32-36 (79%) and NF-B at serine
536 (629.8%) with Ab42 exposure (Figure 4). p65-
mediated transcription is regulated by S536 phosphory-
lation in the transactivation domain (TAD) by a variety
of kinases (TRAF family member-associated NF-B acti-
vator (TANK)-binding kinase (TBK), IKKa, and p38)
through various signalling pathways. This phosphoryla-
tion enhances p65 transactivation potential [45-47].
Pre-incubation with 210 nM C16 significantly pre-
vented activation of IB and NF-B compared to Ab42-
treated cells. The calculated ratios remained comparable
to those obtained without Ab42.
Effects of compound C16 on Ab-induced cytokine
production and release in primary murine mixed co-
cultures
To determine the effect of PKR inhibition on cytokine
levels in our cell lysates and released into the medium,
samples were assayed by ELISA to quantify TNFa, IL-
1b and IL-6 levels. Intracellular levels of these three
cytokines were significantly higher in cells treated with
20 μM Ab42 for 72 h (increase of 86.2% TNFa, 84% IL-
1b and 50.6% IL-6) compared to DMSO-treated cells
(Figure 5A). Treatment with 210 nM C16 significantly
decreased levels of TNFa- and IL-1b-induced Ab42
(83.2% and 60.7% inhibition, respectively) but failed to
prevent IL-6 production (Figure 5A). Cytokine levels
(TNFa and IL-1b) in Ab42-exposed cells pretreated
with 210 nM C16 were comparable to those measured
in the absence of Ab42 (Figure 5A).
Levels of released TNFa and IL-1b were also sig-
nificantly increased after Ab42 exposure (58.3% and
60.7% respectively) compared to DMSO-treated cells
(Figure 5B). As for produced cytokines, the Ab42-induced
release of TNFa and IL-1b was significantly prevented by
210 nM C16 (50.1% and 52.7% inhibition, respectively).
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No significant change was observed for released IL-6, but
levels of produced and released IL-6 remained very low in
our experimental conditions (Figure 5B).
Effects of compound C16 on altered cellular morphology
induced by Ab42 treatment
As we have shown before, Ab42 induced the NF-B sig-
naling pathway and cytokine production, which were
prevented by the inhibitor of PKR, compound C16. The
beneficial effect of C16 has also been analyzed by using
scanning electron microscopy. In micrographs, 20 μM
Ab42 largely affected co-cultures, producing massive
neuronal loss (Figure 6). Axonal and dendritic networks
were also altered with many disruptions of axons and
dendrites, which clearly appeared thinner than with
DMSO or 210 nM C16 treatments. Microglia were acti-
vated and different morphological changes were
observed: microglia cells displayed numerous spiny pro-
cesses along their cell bodies and cytoplasmic projec-
tions, and some cells underwent transformations into
multipolar cells or cells with at least one thin process
extending a distance greater than three times the cell’s
body diameter, known as “process-bearing microglia”.
Some occasional short secondary branches were also
observed (see inset in micrograph of Ab42-treated co-
culture in Figure 6). On the contrary, in C16/Ab42
experimental conditions, microglia looked like smooth
cells with few spines as with DMSO or C16 treatment
without Ab42 treatment. While some neurons were
dead, compared to treatment with DMSO alone, the
network of axons and dendrites was preserved and com-
parable to the network observed with DMSO or C16
treatments (Figure 6).
Effects of compound C16 on Ab42-induced apoptosis
Caspase-3 is known to be a crucial mediator of apop-
tosis through its protease activity. Activation of cas-
pase-3 requires proteolytic processing of its inactive
zymogen into activated fragments after cleavage at
aspartic acid 175. In order to evaluate apoptosis in cell
co-cultures, we studied the activation of caspase-3 in
cell lysates represented by the ratio of cleaved-caspase-
3/total caspase-3 (Figure 7). Results show a great
increase in activation of caspase-3 after Ab42 exposure
for 72 h (97%) compared to DMSO-treated cells. This
activation was totally prevented by 210 nM C16, and
 
 
 
 
 
 
 
 
 
 
DMSO 1 μM C16 210 nM C16 
Figure 1 Cytotoxicity of compound C16 in neuron/astrocyte/microglia co-cultures. Scanning electron micrographs of neuron/astrocyte/
microglia co-cultures prepared from brains of E18 C57Bl/6 mice. These co-cultures were incubated with the specific PKR inhibitor, C16 at 210 nM
or 1 μM, or its DMSO vehicle in serum-free medium. The samples were examined in a JEOL JSM-840 electron microscope. Black or white arrows
point out some microglia cells. Microglia appear as spherical smooth cells in contact with neurons and the astroglial layer in DMSO or 210 nM
C16 conditions. However, in the presence of 1 μM C16, the integrity of cells is greatly altered with disruption of the axonal network, activated
astrocytes with stellar form and microglia that look like macrophages. Scale bars: 10 μm, 15 μm and 20 μm for DMSO, 210 nM C16 and 1 μM
C16, respectively.
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the ratios were comparable to those obtained in
DMSO-treated cells.
During apoptosis, phosphatidylserine is translocated
from the inner to the outer plasma membrane leaflet.
This externalization was analyzed with annexin V-FITC
staining to examine apoptotic states of the different cell
populations after treatment with 210 nM C16 and Ab42
exposure for 72 h (Figure 8). Furthermore, the apoptosis
detection kit includes propidium iodide (PI) to label the
cellular DNA in necrotic cells. This combination allows
the differentiation among early apoptotic cells (annexin
V-FITC-positive, PI-negative), necrotic cells (annexin V-
FITC-positive, PI-positive), and viable cells (annexin V-
FITC-negative, PI-negative). In all conditions examined,
no PI staining associated with annexin V-FITC staining
was observed. The state of necrotic cells was probably at
a maximum, with complete nucleus destruction, explain-
ing the lack of PI staining. Thus, co-staining annexin V-
FITC and cell markers excluded PI incubation in our
protocol. The results show that prominent annexin V-
FITC staining colocalizes with MAP2 staining after
Ab42 exposure, whereas GFAP-positive cells appeared
unaffected (Figure 8A and 8C). We found also a diffuse
and very weak staining of annexin V-FITC in CD68-
positive cells (Figure 8E and 8G). Exposure to 210 nM
C16 yielded no evidence of apoptosis either in neurons
(Figure 8B and 8D) or in microglia (Figure 8F and 8H).
Discussion
Our previous findings indicated that PKR is associated
with apoptotis in brains of APPSLPS1 knock-in trans-
genic mice, and in vitro in Ab42-treated SH-SY5Y neu-
roblastoma cells [27,29,38,43]. Moreover, other studies
have clearly reported that PKR is involved in the activa-
tion of NF-B pathway through phosphorylation of IKK
[32,48,49] and I-B [33] in models of viral infection.
NF-B plays a critical role in many cellular events, such
as expression of cytokine genes that affect inflammatory
process. Concerning AD, NF-B has been shown to be
upregulated and responsible for the induction of TNFa,
IL-1b and IL-6 mRNA [7,50-52], particularly in glial
cells. Furthermore, many studies have shown that Ab
neurotoxicity induces cytokine production and release of
TNFa, IL-1b and IL-6 [8,53,54]. This inflammatory pro-
cess has also largely been described in brain [55,56] and
in the periphery in plasma, serum or mononuclear cells
of patients with AD [19,57]. Although inflammation
might have a neuroprotective role through Ab phagocy-
tosis, it is of interest to better understand the regulation
involved in production of inflammatory factors in AD in
order to limit neuronal death when the inflammatory
process switches to an unregulated phenomenon.
Because of the involvement of PKR in NF-B-mediated
inflammation, we were interested in studying the effect
of PKR inhibition on production of inflammatory factors
in a murine mixed co-culture.
The cell culture model used in this project is an
embryonic (E18) mouse brain co-culture that includes
neurons (36%), astrocytes (57%) and microglia (6%), in
order to reflect the cell population in normal adult
mouse cortex [40]. In control conditions without amy-
loid stress, no inflammatory reactive glia were observed,
excluding any trauma during cell preparation. The
major aim with this model was to be close to physiolo-
gic conditions and to recreate in vitro the essential neu-
ron/glia environment to explore the effects of the
inflammatory process on neurons. Currently, indepen-
dent cultures of microglia or astrocytes with or without
neurons are widely used as models of inflammation in
brain. However, it seemed essential to maintain these
three cellular actors together in our experimental condi-
tions, considering the multiple interactions between
neurons and glia, in particular in inflammatory condi-
tions [58-61]. This model is produced from embryonic
tissue, and one must therefore remain cautious about its
use because, as we know, the maturity of the regulatory
and compensation processes is not complete. The cells
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Figure 2 Immunoreactivity of PT451-PKR in mixed co-cultures.
Representative blots showed immunoreactivity of PT451-PKR and
actin in nuclear extracts of astrocyte/neuron/microlgia co-cultures
treated with either 210 nM C16 or DMSO and exposed to 20 μM
Ab42 for 72 hours at 37°C. Wells of blots correspond to DMSO, C16,
Ab42 and DMSO, Ab42 and C16, from left to right. Data are
reported relative to actin. Results are expressed as percentage of
DMSO control (set at 100%) and are mean ± SEM for 4 experiments.
#p < 0.05, ***p < 0.001 compared to respective controls without
C16 by one-way ANOVA with a Newman-Keuls multiple comparison
test.
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Figure 3 PT451-PKR staining after C16 treatment and Ab42 exposure in mixed co-cultures. (A to H) Confocal staining of PT451-PKR (red
channel), MAP2 (green channel), GFAP (blue channel) and DAPI in Ab42-treated cells previously incubated with DMSO (C, G) or 210 nM C16 (D,
H) compared DMSO (A, E)- or C16 (B, F)-treated cells. (I to P) Confocal staining of PT451-PKR (green channel), CD68 (red channel) and DAPI (blue
channel) in co-cultures in the same experimental conditions described above. PKR was activated under Ab42 exposure (G) compared to DMSO-
and C16-treated cells (E and F, respectively). PT451-PKR is present in neurons, with an intense perinuclear, nuclear and axonal staining compared
to DMSO-treated cells (Fig. 3: C, G compared to A, E). Neurons with nuclear PT451-PKR are shrunken (Fig. 3: C, G). Treatment with C16 decreased
perinuclear and nuclear staining, but some axons remained stained (Fig.3: D, H). No signal of PT451-PKR was observed with only C16 (Fig.3: B, F).
In astrocytes, a diffuse cytoplasmic staining of PT451-PKR and a robust staining in spine-like structures of astrocytic processes with Ab42 (Fig.3: C,
G) is observed and well prevented by C16 treatment (Fig.3: D, H). Microglia are activated with appearance of thick processes and irregular shape
and display a high level of activated PKR after 72 h Ab42 exposure (Fig.3: K, O) compared to DMSO-treated cells (Fig.3: I, M). C16 partially
rescued this activation of PKR in microglia with no thick processes around cell bodies as in DMSO- or C16 conditions alone (Fig.3: L, P compared
to I, M and J, N). Scale Bars: 42 μm.
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DMSO-treated cells (set at 100%). Results are mean ± SEM derived from 5 experiments in duplicate. #p < 0.05, ###p < 0.001 and *p < 0.05,
***p < 0.001 compared to respective controls without C16 by one-way ANOVA with Newman-Keuls multiple comparison test.
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Figure 5 Production (A) and release (B) of cytokines in murine astrocyte/neuron/microglia co-cultures. These co-cultures were pretreated
with 210 nM C16 or its DMSO vehicle and exposed or not to 20 μM Ab42 for 72 h in serum-free medium. TNFa, IL-1b and IL-6 were assessed
by ELISA. Data are expressed as mean ± SEM of pg/mg protein for production and pg/mL for release (n = 5 in duplicate). *p < 0.05, **p < 0.01,
***p < 0.001 compared to DMSO; #p < 0.05, ##p < 0.01 and ###p < 0.001 compared to Ab42 DMSO after one-way ANOVA with Newman-Keuls
multiple comparison test.
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may be more or less vulnerable to the toxicity of amy-
loid peptide compared with adult cells. Their tolerance
system has not yet been sufficiently explored. In addi-
tion, the concentration of exogenous amyloid peptide
added in cultures, although identical to that used in
many published studies, is far greater to that found in
brains of patients with Alzheimer’s disease. However, it
is known that levels of both Abx-40 and Abx-42
increase very early in the disease process, and in the
frontal cortex these increases occurr in the absence of
significant neurofibrillary pathology. These levels
increase systematically with severity of cognitive decline
contrary to Ab burden as assessed only in neuritic
plaques [62].
For this mixed co-culture model, we have shown
that the PKR inhibitor at a concentration of 1 μM, as
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DMSO 
DMSO + Aβ42 
C16 
C16 + Aβ42 
Figure 6 Scanning electron micrographs of neuron/astrocyte/microglia co-cultures. These co-cultures were preincubated with compound
C16 at 210 nM or DMSO 1 h before treatment with 20 μM Ab42 or distilled water for 72 h in a serum-free medium. As in figure 1, samples
were examined in a JEOL JSM-840 electron microscope. Ab42 strongly altered the axonal and dendritic network, compared to DMSO or 210 nM
C16 conditions. Microglia are activated and display numerous spinous processes along cell bodies and cytoplasmic projections; some cells have
undergone transformation into multipolar cells or cells with at least one thin process extending a distance greater than three times the cell
body diameter, known as “process-bearing microglia”. Some occasional short secondary branches were also observed. Insets showed different
states of activated microglia in Ab42-treated co-cultures. On the contrary, C16 prevented the activated state of microglia, which appear as
smooth cells with few spines as in DMSO or C16 without Ab42 treatment. While some neurons were dead compared to DMSO alone, the
network of axons and dendrites is preserved and comparable to the network observed in DMSO or C16 conditions. Bars: 17 μm and 5 μm for
DMSO and 15 μm and 6 μm for C16, 35 μm and 10 μm for DMSO + Ab42, 14 μm and 6 μm for C16 + Ab42, at low and high magnification,
respectively. White arrows indicate microglia cells.
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previously used on neuroblastoma cell line [43], induces
a great alteration, leading us to use a lower concentra-
tion of 210 nM corresponding to the IC50 [37]. This
concentration was effective in inducing a decrease of
PKR phosphorylation on threonine 451 by 33% in cells
exposed to 20 μM Ab42 for 72 h.
By immunostaining, we showed that Ab42 induces
activation of PKR in neurons with a perinuclear and
nuclear localization as we have previously described
[38], but also in glia where PKR is highly activated in
spine-like structures of astrocytic processes and in the
cytoplasm of microglia. Expression of PKR is known in
astrocytes to be among an array of receptors involved in
innate immunity [63] but this expression has not yet
been described in microglia. Treatment of these three
cellular types with 210 nM C16 before Ab42 exposure
for 72 h decreased PT451-PKR staining, but a residual
amount of activated PKR remained. These findings were
also associated with a more preserved integrity of the
cells compared to Ab42-treated cultures without C16.
Indeed, two spectacular cellular events were clearly pro-
tected: the dendritic and axonal network of neurons and
the morphology of microglia. In Ab conditions, many of
the neurons showed signs of neuritic damage with bead-
ing and fragmentation, according to other studies
[64-66], and formation of pleiomorphic microglia was
observed with ramified microglia and features of chroni-
cally activated microglial cells represented by a markedly
elongated cells named rod microglia. In brains of
patients with AD, activated rod and ramified microglia
are observed: ramified microglia are in contact with
amyloid fibrils and rod microglia are found predomi-
nantly at the edge of senile plaques [67,68]. For astro-
cytes, morphological modifications were very limited
with thinner extensions. This mixed co-culture model of
AD displayed the morphological degeneration and glial
activation seen in AD, which was rescued by pretreat-
ment with C16.
Besides the role of C16 in the rescue of the integrity
of co-cultures, we found that this PKR inhibitor induced
also a significant decrease in Ab42-induced I-B and
NF-B activation, bringing their activation rates back
close to those observed without exposure. A previous
study using the overexpression of sirtuin 1 (SIRT1) dea-
cetylase and the addition of the SIRT1 agonist resvera-
trol showed markedly reduced NF-B signaling
stimulated by Ab with strong neuroprotective effects in
primary mixed neuronal/glial cultures from rat cortices
[69]. Moreover, it is interesting to note that inhibition
of the many kinases involved in the NF-B pathway by
META060 showed an ability to suppress in vitro and ex
vivo LPS-mediated inflammation [70].
Taken together, these results led us to investigate
cytokine production and release after C16 treatment.
Our results obtained by ELISA show a robust inhibition
of Ab42-induced production and release of both TNFa
and IL-1b but, surprisingly, we did not find any modifi-
cation for IL-6 by pretreatment with C16. While levels
of IL-6 were significantly higher than in vehicle condi-
tions, the amounts remained very low whatever the con-
ditions. It is known that astrocytes are the major source
of IL-6 in CNS injury and inflammation [71]. Many sti-
muli can upregulate IL-6 production, in particular
TNFa and IL-1b [72], but concentrations required to
induce IL-6 production in human astrocytes are higher
than 1 ng/mL [73] whereas, in our model, concentra-
tions of TNFa and IL-1b were lower than 600 pg/mL.
Although we showed a robust increase in TNFa and IL-
1b after 72 h of Ab42 exposure, it seems that this
increase was insufficient to induce IL-6 production in
astrocytes. Microglia can also produce IL-6, but a recent
study revealed that microglia from young mice are less
responsive to stimulation and secrete lower levels of IL-
6 than do microglia from aged mice [74]. In addition,
many studies have reported no modification of IL-6
expression or secretion in spite of IL-1b treatment of
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Figure 7 C16 prevented activation of caspase-3. Representative
blots show the immunoreactivity of procaspase-3, cleaved caspase-3
fragments and tubulin in astrocyte/neuron/microglia co-cultures
pretreated with 210 nM of C16 compared to vehicle treatment and
with or without 20 μM Ab42 exposure for 72 h. Data of cleaved-
caspase-3 are reported relative to data of corresponding
procaspase-3. Results are expressed as percentage of DMSO
condition (set at 100%) and are mean ± SEM for 4 experiments in
duplicate. ##p < 0.01 and ***p < 0.001, compared to respective
controls without C16 by one-way ANOVA with Newman-Keuls
multiple comparison test.
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primary astrocytes or primary microglia cultures, with or
without neurons [75] related to serum-free conditions
[54], b-amyloid protein structure [76], or glutathione
concentration [77]. While there are few experiments
using mixed cultures of neurons and glial cells, one
study showed that 10 μM Ab42, previously aggregated,
induced a decrease of IL-6 levels after two days of incu-
bation [78]. These contradictory results regarding effects
on IL-6 levels of Ab in vitro have also been obtained for
brains, peripheral cells, serum and plasma of patients
with AD [8].
TNFa seems to be a critical mediator of the effects of
neuroinflammation on early (pre-plaque) pathology in
3xTgAD mice, and its inhibition in the CNS may slow
the appearance of amyloid-associated pathology, cogni-
tive deficits, and potentially the progressive loss of neu-
rons in AD [79]. These results support the observations
made a year before concerning the inhibition of TNFa
by thalidomide showing a capacity to prevent amyloid
beta-induced impairment of recognition memory in
mice treated by intracerebral ventricular injection of
Ab25-35 [80]. Finally, neutralizing the TNFa pathway
by etanercept prevents behavioural changes in an
inflammatory rat model obtained by microinjection of
IL-1b into the hypothalamus [81].
It has also been shown that ibuprofen suppresses IL-
1b induction and ameliorates b-amyloid pathology in
APPswe (Tg2576) mice [82]. Thus, preventing both
TNFa and IL-1b production would seem to be an effi-
cient strategy to slow damage observed in AD models.
To check these literature data suggesting a protective
effect of the regulation of inflammation, we studied the
apoptotic state of our co-cultures. We show that beyond
the inhibition of both Ab42-induced TNFa and IL-1b
production and release, cells in co-cultures display sig-
nificant reduction of activated pro-apoptotic caspase-3
after PKR inhibitor treatment. Caspase-3 is able to
cleave PKR to generate active PKR N-terminal and C-
terminal fragments that play a role in the activation of
intact PKR [42,83] and contribute to the apoptotic pro-
cess [84]. Moreover, staining with annexin V-FITC has
specified that apoptosis is induced in neurons with axo-
nal processes drastically altered by Ab42, according to
previous studies [64], and that the PKR inhibitor com-
pletely prevents this initiation of apoptosis in neurons,
displaying a preserved integrity. Although no positive PI
staining associated with annexin V-FITC was observed,
probably due to nuclear lysis, cellular debris are absent
in the presence of compound C16, indicating also that
this PKR inhibitor prevents Ab42-induced necrosis. A
signal of annexin V-FITC was also observed in a few
activated microglia in Ab42-treated co-cultures and we
can underline that pretreatment with C16 rescued the
morphology of microglia from rod microglia to round
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Figure 8 C16 prevented apoptosis in neurons. Confocal staining of annexin V-FITC (green channel) with MAP2 (red channel) and GFAP (blue
channel) (A, B, C and D) or with CD68 (red channel) (E, F, G and H) after 20 μM Ab42 exposure and treated with 210 nM of C16 or DMSO for
72 h. A, B, E and F are merged images and C, D, G and H show only annexin-V-FITC staining. DAPI was used as a nuclear stain. A strong annexin
V-FITC staining colocalizes with MAP2 staining after Ab42 exposure, whereas GFAP-positive cells appear unaffected (A, C). We found also a
diffuse and very weak staining of annexin V-FITC in CD68-positive cells (E, G). C16 prevented translocation of phosphatidylserine from the inner
to the outer plasma membrane leaflet both in neurons (B, D) and microglia (F, H). Photos are representative of 4 experiments. Scale Bars: 40 μm.
Couturier et al. Journal of Neuroinflammation 2011, 8:72
http://www.jneuroinflammation.com/content/8/1/72
Page 13 of 17
microglia and astrocytes from spider-like to protoplas-
mic structures. It is well known that caspase-3 is a key
factor in TNFa- and IL-1b-induced apoptosis and neu-
ronal loss in AD [85]. Moreover studies described a
major role for TNFa and IL-1b in caspase-3 activation
[86,87]. These findings are consistent with the preven-
tion of apoptosis observed in our model through
decreases of only TNFa and IL-1b.
In astrocytes and microglia, PKR, highly cytoplasmic,
could be involved in the modulation of the production
of inflammatory factors. This suggestion is supported by
a study reporting PKR functions as an essential modula-
tor in inflammatory signaling events. They revealed that
activation of PKR by LPS leads to induction of inter-
feron-b through activation of NF-B, triggering phos-
phorylation of STAT1 in rat brain glial cells [88].
Furthermore, it was described that b-amyloid peptides
induce degeneration of cultured rat microglia [89].
Thus, microglia might be unable to function normally
and to properly respond to amyloid stimulus. Recent
papers have underlined the senescence of microglia in
AD, with loss of their neuroprotective properties, pre-
ceding the onset of tau pathology [90], suggesting that
breakdown of the brain’s immune system may be an
important factor in the development of neurodegenera-
tion [91]. PKR inhibition, which prevents Ab42-induced
morphologic alterations of microglia, could limit the
degeneration of microglia and restore a normal profile
of inflammatory functions.
Conclusions
Our results highlight the involvement of PKR in the
inflammatory response to Ab42 by using primary mur-
ine mixed co-cultures allowing interactions between
neurons, astrocytes and microglia. Interestingly, the sig-
nificant decrease of Ab42-induced cytokine production
and release by a specific inhibitor of PKR was associated
with preserved integrity of cells and rescue from apopto-
sis. Note that the compound C16 was added once before
a 72 h-time incubation of mixed co-cultures with Ab42,
indicating its efficiency at IC50 in time. These findings
could strengthen therapeutic strategies aimed at pre-
venting deregulated inflammatory process in AD models
through a very specific signaling pathway. In our labora-
tory, in vivo experiments with APPswePS1dE9 trans-
genic mouse model have been performed to determine
if this specific PKR inhibitor could be relevant in the
treatment of AD (data submitted).
Additional material
Additional file 1: Immunostaining of neurons, astrocytes and
microglia in primary mixed murine cultures. A fourfold confocal
staining (DAPI, MAP-2, GFAP, CD68 for nuclei, neurons, astrocytes and
microglia, respectively) was used to count neurons, astrocytes and
microglia in mixed co-cultures.
Additional file 2: State of exogenous Ab42 assembly in primary
mixed murine cultures. State of Ab42 aggregations after 72 h
incubation in neuron/astrocyte/microglia cultures using immunoblotting
and scanning electron microscopy in our experimental conditions.
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